<DOC>
	<DOCNO>NCT02867800</DOCNO>
	<brief_summary>To assess tolerability costimulation block agent abatacept ( CTLA4-Ig ) add standard graft versus host disease ( GVHD ) prophylaxis regimen calcineurin inhibitor methotrexate patient receive early alemtuzumab follow fludarabine , thiotepa , melphalan , alemtuzumab conditioning .</brief_summary>
	<brief_title>Abatacept GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation Pediatric Sickle Cell Disease</brief_title>
	<detailed_description>Outcomes hematopoietic stem cell transplantation ( HSCT ) child adolescent sickle cell disease ( SCD ) improve . Graft versus host disease ( GVHD ) , however , remain barrier success . GVHD account transplant relate mortality much morbidity setting-in part injury directly cause part deleterious effect steroid immunosuppressive agent use prevent treat . The result pre-clinical study phase I clinical study patient hematologic malignancy suggest costimulation block agent CTLA4-Ig may hold promise agent GVHD prophylaxis . In present trial , assess tolerability add abatacept standard GVHD prophylaxis-a calcineurin inhibitor methotrexate-in pediatric SCD patient receive early alemtuzumab ( complete day -18 ) follow fludarabine , thiotepa , melphalan conditioning . This trial provide foundation subsequent trial design test long-term hypothesis abatacept safe , steroid-sparing effective adjunct standard GVHD prophylaxis setting .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Meperidine</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>1 . Patients Hgb SS SB0 thalassemia age 3 20.99 year least 10 kg get HLA match bone marrow transplant , eligible increase risk GVHD severe SCD . ( ) Patients fall one follow three group consider increase risk GVHD : ( ) Are 10 20.99 year receive transplant HLA match related donor . ( ii ) Are 3 9.99 year receive transplant HLA match related donor least 10 year . ( iii ) Are 3 20.99 year receive transplant HLA match unrelated donor . Donors must match A , B , C DRB1 loci allele level . ( b ) Patients meet one follow criterion qualify severe SCD : ( ) Previous clinical stroke , evidence neurological deficit lasting longer 24 hour , accompany radiographic evidence ischemic brain injury cerebral vasculopathy . ( ii ) Asymptomatic cerebrovascular disease , evidence one following : Progressive silent cerebral infarction , evidence serial MRI scan demonstrate development succession lesion ( least two temporally discreet lesion , measure least 3 mm great dimension recent scan ) enlargement single lesion , initially measure least 3 mm ) . Lesions must visible T2weighted MRI sequence . Cerebral arteriopathy , evidence abnormal TCD testing ( confirm elevate velocity single vessel TAMMV &gt; 200 cm/sec nonimaging TCD ) significant vasculopathy MRA ( great 50 % stenosis &gt; 2 arterial segment complete occlusion single arterial segment ) . ( iii ) Frequent ( ≥ 3 per year precede 2 year ) painful vasoocclusive episode ( defined episode last ≥ 4 hour require hospitalization outpatient treatment parenteral opioids ) . If patient hydroxurea use associate decrease frequency episode , frequency gauge 2 year prior start drug . ( iv ) Recurrent ( ≥ 3 lifetime ) acute chest syndrome event necessitate erythrocyte transfusion therapy . ( v ) Any combination ≥ 3 acute chest syndrome episode vasoocclusive pain episode ( define ) yearly 3 year . If patient hydroxurea use associate decrease frequency episode , frequency gauge 3 year prior start drug . 2 . All patient and/or parent legal guardian must sign write informed consent . Assent , appropriate , obtain accord institutional guideline . 3 . Must evaluate adequately counseled regard treatment option severe SCD pediatric hematologist . 4 . Because elective nonurgent nature HSCT SCD , important patient family counsel regard fertility preservation measure available . All patient and/or parent legal guardian must indicate consent assent form receive counsel . 1 . Bridging ( portal portal ) fibrosis cirrhosis liver . 2 . Parenchymal lung disease stem SCD process define DLCO ( correct hemoglobin ) force vital capacity le 45 % predict . Children unable perform pulmonary function test exclude require daytime oxygen supplementation . 3 . Renal dysfunction estimate GFR &lt; 50 % predict normal age . 4 . Cardiac dysfunction shorten fraction &lt; 25 % . 5 . Neurologic impairment hemiplegia , define fullscale IQ ≤70 , quadriplegia paraplegia , inability ambulate , impairment result decline Lansky performance score &lt; 70 % . 6 . Clinical stroke within 6 month anticipate transplant . 7 . Karnofsky Lansky functional performance score &lt; 70 % . 8 . Patient HIV infect . 9 . Donor HIV infect . 10 . Donor Hgb SS , SC SB0 thalassemia . 11 . Patient unspecified chronic toxicity serious enough detrimentally affect patient 's capacity tolerate bone marrow transplantation . 12 . Patient patient 's guardian ( ) unable understand nature risk inherent BMT process . 13 . History lack compliance medical care would jeopardize transplant course . 14 . Donor psychological , physiologic , medical reason unable tolerate bone marrow harvest receive general anesthesia . 15 . Active viral , bacterial , fungal protozoal infection . 16 . Donor pregnant . 17 . Patient pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Sickle Cell Disease</keyword>
	<keyword>Graft Versus Host Disease</keyword>
	<keyword>Abatacept</keyword>
	<keyword>Hematopoietic Stem Cell Transplantation</keyword>
</DOC>